{"DataElement":{"publicId":"7413937","version":"1","preferredName":"Reported Name of Procedure Non-cellular Immunotherapy Type","preferredDefinition":"The verbatim surgical, therapeutic, or diagnostic procedure's name for non-cellular immunotherapy.","longName":"PR_PRTTRT_NCIMMTx","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6411454","version":"1","preferredName":"Procedure Domain Reported Name of Procedure","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure._The literal identifier of the procedure.","longName":"6407261v1.0:6411452v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6407261","version":"1","preferredName":"Procedure Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure.","longName":"C102700","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procedure Domain","conceptCode":"C102700","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73F3626C-19A3-3896-E053-F662850A4518","latestVersionIndicator":"Yes","beginDate":"2018-08-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-21","modifiedBy":"ONEDATA","dateModified":"2018-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6411452","version":"1","preferredName":"Reported Name of Procedure","preferredDefinition":"The literal identifier of the procedure.","longName":"C117511","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reported Name of Procedure","conceptCode":"C117511","definition":"The literal identifier of the procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"74229DA7-7B00-77CA-E053-F662850AEC9E","latestVersionIndicator":"Yes","beginDate":"2018-08-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-23","modifiedBy":"ONEDATA","dateModified":"2018-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"74229DA7-7B11-77CA-E053-F662850AEC9E","latestVersionIndicator":"Yes","beginDate":"2018-08-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-23","modifiedBy":"TAYLORT","dateModified":"2020-07-20","changeDescription":"7-20-20 tmt released. Created as part of the CDISC mapping task_ghd_08.23.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7136496","version":"1","preferredName":"Non-cellular Immunotherapy Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"7136496v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other bispecific engager","valueDescription":"Other bispecific engager","ValueMeaning":{"publicId":"7136497","version":"1","preferredName":"Other bispecific engager","longName":"7136497","preferredDefinition":"Other bispecific engager","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BD0CEEA-D28E-32A6-E053-F662850A1DE0","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BD0CEEA-D2A7-32A6-E053-F662850A1DE0","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","deletedIndicator":"No"},{"value":"Blinatumomab","valueDescription":"Blinatumomab","ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BD0CEEA-D2B1-32A6-E053-F662850A1DE0","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","deletedIndicator":"No"},{"value":"Other targeted antibody","valueDescription":"Other targeted antibody","ValueMeaning":{"publicId":"7136498","version":"1","preferredName":"Other targeted antibody","longName":"7136498","preferredDefinition":"Other targeted antibody","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BD0CEEA-D2BB-32A6-E053-F662850A1DE0","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BD0CEEA-D2D4-32A6-E053-F662850A1DE0","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","deletedIndicator":"No"},{"value":"Inotuzumab Ozogamicin","valueDescription":"Inotuzumab Ozogamicin","ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BD0CEEA-D2DE-32A6-E053-F662850A1DE0","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"ONEDATA","dateModified":"2020-01-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BD0CEEA-D278-32A6-E053-F662850A1DE0","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-10","modifiedBy":"SETRAKIN","dateModified":"2020-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the type of Non-cell","type":"Preferred Question Text","description":"What was the type of Non-cellular Immunotherapy?","url":null,"context":"COG"}],"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AED4275A-DCFB-3785-E053-4EBD850A3B00","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-08","modifiedBy":"SETRAKIN","dateModified":"2020-09-21","changeDescription":"7-20-20 tmt released for Theradex reuse. Created as part of the CDISC mapping task_ghd_08.23.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}